Cargando…

A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer

PURPOSE: Germ cell tumors (GCTs) are cured with therapy based on cisplatin, although a clinically significant number of patients are refractory and die of progressive disease. Based on preclinical studies indicating that refractory testicular GCTs are hypersensitive to hypomethylating agents (HMAs),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Albany, Costantine, Fazal, Zeeshan, Singh, Ratnakar, Bikorimana, Emmanuel, Adra, Nabil, Hanna, Nasser H., Einhorn, Lawrence H., Perkins, Susan M., Sandusky, George E., Christensen, Brock C., Keer, Harold, Fang, Fang, Nephew, Kenneth P., Spinella, Michael J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826483/ https://www.ncbi.nlm.nih.gov/pubmed/33135391 http://dx.doi.org/10.1002/cam4.3583

Ejemplares similares

Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine
por: Albany, Costantine, et al.
Publicado: (2016)

Very late relapse of germ cell tumor as a teratoma: a case report and review of the literature
por: Arafat, Waddah, et al.
Publicado: (2014)

Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumors
por: Singh, Ratnakar, et al.
Publicado: (2019)

Epigenetic Remodeling through Downregulation of Polycomb Repressive Complex 2 Mediates Chemotherapy Resistance in Testicular Germ Cell Tumors
por: Singh, Ratnakar, et al.
Publicado: (2019)

Between a Rock and a Hard Place: An Epigenetic-Centric View of Testicular Germ Cell Tumors
por: Singh, Ratnakar, et al.
Publicado: (2021)

Systemic immune-inflammation index in germ-cell tumours: search for a biological prognostic biomarker
por: Albany, Costantine
Publicado: (2018)

Management of Chemotherapy Induced Nausea and Vomiting in Patients on Multiday Cisplatin Based Combination Chemotherapy
por: Ranganath, Praveen, et al.
Publicado: (2015)

Germ Cell Tumors: Updates on Epidemiology, Biology, and Treatment Considerations
por: Bagrodia, Aditya, et al.
Publicado: (2018)

Salvage therapy for relapsed testicular cancer
por: Adra, Nabil, et al.
Publicado: (2017)

Salvage therapy for relapsed testicular cancer
por: Adra, Nabil, et al.
Publicado: (2017)

Emerging Prognostic Biomarkers in Testicular Germ Cell Tumors: Looking Beyond Established Practice
por: Chovanec, Michal, et al.
Publicado: (2018)

Anti-myelin-associated glycoprotein peripheral neuropathy as the only presentation of low grade lymphoma: a case report
por: Albany, Costantine
Publicado: (2009)

Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study
por: Fenaux, Pierre, et al.
Publicado: (2023)

Mass balance and metabolite profiling of (14)C-guadecitabine in patients with advanced cancer
por: Roosendaal, Jeroen, et al.
Publicado: (2019)

Nephrotoxicity of perfluorooctane sulfonate (PFOS)—effect on transcription and epigenetic factors
por: Wen, Yi, et al.
Publicado: (2022)

Disabling osteomalacia and myopathy as the only presenting features of celiac disease: a case report
por: Albany, Costantine, et al.
Publicado: (2009)

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia
por: Roboz, Gail J., et al.
Publicado: (2017)

Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia
por: Chung, Woonbok, et al.
Publicado: (2019)

Molecular mechanisms of Guadecitabine induced FGFR4 down regulation in alveolar rhabdomyosarcomas
por: Darvishi, Emad, et al.
Publicado: (2020)

Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma
por: Wong, Jonathan, et al.
Publicado: (2022)

Reciprocal epigenetic remodeling controls testicular cancer hypersensitivity to hypomethylating agents and chemotherapy
por: Singh, Ratnakar, et al.
Publicado: (2021)

G0S2 promotes antiestrogenic and pro-migratory responses in ER+ and ER- breast cancer cells
por: Corbet, Andrea K., et al.
Publicado: (2023)

Heat shock and other apoptosis-related proteins as therapeutic targets in prostate cancer
por: Albany, Costantine, et al.
Publicado: (2014)

Simultaneous Modeling of Biomarker and Toxicity Response Predicted Optimal Regimen of Guadecitabine (SGI‐110) in Myeloid Malignancies
por: Xu, Cong, et al.
Publicado: (2017)

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
por: Papadatos-Pastos, Dionysis, et al.
Publicado: (2022)

DNA Methyltransferase 1 Targeting Using Guadecitabine Inhibits Prostate Cancer Growth by an Apoptosis-Independent Pathway
por: Karan, Dev, et al.
Publicado: (2023)

Toward a Mechanistic Understanding of Poly- and Perfluoroalkylated Substances and Cancer
por: Boyd, Raya I., et al.
Publicado: (2022)

Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma
por: Jueliger, Simone, et al.
Publicado: (2016)

Decitabine reactivated pathways in platinum resistant ovarian cancer
por: Fang, Fang, et al.
Publicado: (2014)

Epstein-Barr virus myelitis and Castleman's disease in a patient with acquired immune deficiency syndrome: a case report
por: Albany, Costantine, et al.
Publicado: (2011)

Targeting of Deregulated Wnt/β-Catenin Signaling by PRI-724 and LGK974 Inhibitors in Germ Cell Tumor Cell Lines
por: Schmidtova, Silvia, et al.
Publicado: (2021)

A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
por: Jang, H. Josh, et al.
Publicado: (2023)

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
por: Sébert, Marie, et al.
Publicado: (2019)

Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial
por: Noviello, Teresa Maria Rosaria, et al.
Publicado: (2023)

Semen and serum platinum levels in cisplatin‐treated survivors of germ cell cancer
por: Malone, Eoghan R., et al.
Publicado: (2021)

The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer
por: Luker, Andrea J., et al.
Publicado: (2020)

A Novel ALDH1A1 Inhibitor Blocks Platinum-Induced Senescence and Stemness in Ovarian Cancer
por: Muralikrishnan, Vaishnavi, et al.
Publicado: (2022)

Epigenetics in Prostate Cancer
por: Albany, Costantine, et al.
Publicado: (2011)

Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells
por: Amaro, Adriana, et al.
Publicado: (2023)

Primary malignant mediastinal germ cell tumours: improved prognosis with platinum-based chemotherapy and surgery.
por: Childs, W. J., et al.
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_pbm45sbavq49ou1h18vglcuqo8